54
Participants
Start Date
May 24, 2023
Primary Completion Date
January 30, 2026
Study Completion Date
July 31, 2027
Amivantamab
Low fucose, fully human immunoglobulin gamma-1-based bispecific antibody directed against EGFR and MET tyrosine kinase receptors. It shows clinical activity against tumors with the primary activating EGFR mutations Exon 19del or Exon 21 L858R substitution, EGFR Exon 20ins mutations, the EGFR resistance mutations Threonine790Methionine (T790M) or Cysteine797Serine (C797S), and activation of the Mesenchymal Epithelial Transition (MET) pathway.
Lazertinib
It selectively inhibits both primary activating EGFR mutations (Exon 19del, Exon 21 L858R substitution) and the EGFR T790M resistance mutation, while having less activity versus wild-type EGFR.
Pemetrexed 500 mg
Inhibits enzymes involved in folate-dependent metabolism, thereby disrupting cellular replication.
Hospital de Amor de Barretos, Barretos
Pronutrir - Oncologia e Nutrição, Fortaleza
Hospital Evangélico de Cachoeiro de Itapemirim, Cachoeiro de Itapemirim
Hospital Erasto Gaertner, Curitiba
Liga Norte Riograndense Contra o Câncer, Natal
Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre
Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS, Porto Alegre
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto
Hospital de Base de São José do Rio Preto, São José do Rio Preto
INCA - Instituto Nacional de Câncer, Rio de Janeiro
Centro de Tratamento de Tumores Botafogo (Oncoclínicas), Rio de Janeiro
ICESP - Instituto do Câncer do Estado de São Paulo, São Paulo
BP - A Beneficência Portuguesa de São Paulo, São Paulo
São Camilo Oncologia, São Paulo
Janssen, LP
INDUSTRY
Latin American Cooperative Oncology Group
OTHER